Dr. Marc Vidal serves as Vice President of Chemistry at Thryv Therapeutics, where he leads the company’s chemistry initiatives, including drug design and CMC operations.

Prior to joining Thryv, Dr. Vidal worked at Gladius Pharmaceuticals from 2016 to 2019, initially as a Research Scientist, where he designed and executed multi-step syntheses to develop a library of cephalosporin-based compounds targeting multi-drug-resistant bacterial infections. He later advanced to Head of Chemistry, overseeing CMC operations and compound development.

Dr. Vidal earned his chemical engineering degree from École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN) in France. He then obtained his PhD in Organic Chemistry from the Université de Montréal, where he developed and studied a novel class of anion transporters. Following his PhD, he pursued postdoctoral research at the Université de Montréal, focusing on molecularly imprinted polymers for the capture of small compounds.